Proteins linked to neurodegenerative diseases can potentially be used as biomarkers. A study now shows that after accounting for confounding variables such as age and blood contamination, cerebrospinal fluid levels of α-synuclein and DJ1 are substantially reduced in patients with Parkinson disease compared with healthy controls or individuals with Alzheimer disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease
Scientific Reports Open Access 29 August 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752 (2006).
Hardy, J., Lewis, P., Revesz, T., Lees, A. & Paisan-Ruiz, C. The genetics of Parkinson's disease: a critical review. Curr. Opin. Genet. Dev. 19, 254–265 (2009).
El-Agnaf, O. M. et al. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945–1947 (2003).
Hong, Z. et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713–726 (2010).
Mollenauer, B. et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315–325 (2008).
Waragi, M. et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967–972 (2006).
Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162–166 (2006).
Sunderland, T. et al. Decreased β-amyloid 1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094–2103 (2003).
Fukumoto, H. et al. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. doi: 10.1096/fj.09-150359.
El-Agnaf, O. M. et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419–425 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Foulds, P., Mann, D., Mitchell, J. et al. Progress towards a molecular biomarker for Parkinson disease. Nat Rev Neurol 6, 359–361 (2010). https://doi.org/10.1038/nrneurol.2010.78
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.78
This article is cited by
-
Estimation of dysregulated pathway regions in MPP+ treated human neuroblastoma SH-EP cells with structural equation model
BioChip Journal (2015)
-
Transcriptional regulation analysis in a neurotoxin-induced apoptosis of human neuroblastoma SH-EP cells with a state space model
BioChip Journal (2014)
-
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease
Scientific Reports (2013)